Eisai Faces More Suits Tying Diet Drug Belviq to Cancer (1)

June 12, 2020, 2:47 PMUpdated: June 12, 2020, 3:06 PM

Eisai Pharmaceuticals Inc. and Arena Pharmaceuticals Inc. concealed cancer-related dangers of the now-withdrawn weight-loss drug Belviq, according to a new federal court suit by a New York woman who alleges it caused her thyroid cancer.

The drugmakers face other litigation linking cancer to its weight-loss drug, including a proposed class suit alleging its medical risks outweigh its benefits.

Deborah Steinman used Belviq from November 2014 through February 2017, along with a reduced-calorie diet and increased physical activity for chronic weight management, her complaint in the U.S. District Court for the Eastern District of New York says. Steinman’s thyroid cancer was ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.